VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis. Haematologica. 100:479-488.
authors with profiles
HAGOP M KANTARJIAN